Home > Healthcare > Medical Services > Mitochondrial Myopathies Diagnosis & Treatment Market

Mitochondrial Myopathies Diagnosis & Treatment Market Trends

Report ID: GMI9414
Published Date: May 2024
Report Format: PDF

Download Free Sample

Mitochondrial Myopathies Diagnosis & Treatment Market Trends

The absence of efficacious treatments for mitochondrial disorders, such as mitochondrial myopathy, has prompted intensified research efforts supported by augmented funding. These endeavours aim to meet the worldwide need for accurate diagnosis and effective treatment.

For instance, in September 2023, the Eunice Kennedy Shriver National Institute of Child Health and Human Development granted USD 3.1 million to the University of Arkansas to investigate pediatric mitochondrial disorders. This funding aimed to support the study of mitochondrial functionality and characterization, potentially enhancing treatment efficacy and widening therapeutic options. Therefore, the surge in research funding aimed at expediting the development of effective treatments expands opportunities within the market.

Furthermore, growing advancements in diagnostic technologies and rising emphasis on personalized medicine and targeted therapies further fuel the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of mitochondrial myopathies diagnosis & treatment was reached USD 23.8 million in 2023 and is projected to expand at 6.3% CAGR from 2024 to 2032, due to the increasing prevalence of mitochondrial disorders globally.

The MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) segment in the mitochondrial myopathies diagnosis & treatment market may reach USD 19.8 million by 2032, owing to the high prevalence rate and distinctive clinical presentation.

U.S. mitochondrial myopathies diagnosis & treatment industry size was worth over USD 9.8 million in 2023, due to the presence of healthcare infrastructure, high prevalence of the condition, regulatory frameworks, reimbursement policies, and growing patient awareness.

Abcam Limited, Abliva AB, Blueprint Genetics Oy., Centogene N.V., GeneDx, LLC, GenSight Biologics, Kaneka Corporation, Khondrion, Reata Pharmaceuticals, and Stealth BioTherapeutics are some of the leading mitochondrial myopathies diagnosis & treatment companies worldwide.